FDA Warning Letter

An FDA Warning Letter is the agency’s formal notice to a company that it has found a significant violation of federal law. FDA publishes these letters on its website, names the recipient, describes the violations, and generally expects a written response within 15 working days. They are public documents, searchable by anyone.

In the GLP-1 space they have become a useful map of where the problems are. FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including marketing directly to consumers; active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 substances to compounders; and outsourcing facilities for repackaging retatrutide. Retatrutide and cagrilintide cannot lawfully be used in compounding at all, and they are not components of any FDA-approved drug.

A warning letter is not a lawsuit and not a recall. It is a step before those — a documented finding that puts a company on notice. Some recipients fix the problems quickly; some do not, and enforcement escalates to seizures or injunctions. What a letter reliably tells you is that a trained inspector looked and found something wrong.

The misreading to avoid runs both ways. A letter to a pharmacy does not mean your vial is contaminated. And the absence of a letter does not mean a company is clean — FDA inspects on a risk-based schedule and cannot look everywhere. The useful move is to treat a letter as a reason to ask specific questions rather than as a verdict.

If you are using a compounded product, it is worth searching the FDA warning letter database for the pharmacy and the telehealth company by name before your next refill, and asking your provider directly whether either has received one. Our pharmacy lookup and compounded impurity review explain what the findings usually involve.